Omneity® Pellets
All-In-One Vitamin & Mineral Pellet
Topic:Vaccine development
Vaccine development in horses involves the creation and refinement of immunizations to protect equine populations from infectious diseases. This process includes identifying antigens, formulating vaccines, and evaluating their safety and efficacy through clinical trials. Vaccines stimulate the horse's immune system to recognize and combat specific pathogens, thereby reducing the incidence and severity of diseases. Common equine vaccines target diseases such as equine influenza, tetanus, and West Nile virus. This page compiles peer-reviewed research studies and scholarly articles that explore the methodologies, challenges, and advancements in vaccine development for equine health.
Stability of viability and immunizing potency of lyophilized, modified equine arteritis live-virus vaccine. The Bucyrus strain of equine arteritis virus, previously modified to avirulence and vaccinal virus by 131 serial passages in primary cell cultures of horse kidney followed by 111 passages in primary cell cultures of rabbit kidney, was further passaged in cultures of the E. Derm (NBL-6) cell line, a continuous diploid cell line. Pools of the 16th and 25th passages of the virus in this last equine dermal cell line were lyophilized and stored in lots at 37 C, 23 to 28 C, 4C, and -20 C. The viability of the vaccinal virus deteriorated rapidly during storage at 37 C and at 23 to 28 C, but was relat...
Active immunisation of horses against tetanus including the booster dose and its application. Successful active immunisation of horses against tetanus is dependent on a number of factors of which the toxoid preparation used, its method of application and the ability of the individual horse to respond are fundamental. Two immunisation schedules using an aluminium-based toxoid preparation were examined and the protection determined by monitoring the level of antitoxin afforded by each schedule. The results obtained demonstrated that 2 doses of this toxoid are necessary to ensure 12 months protection in all horses. These results are discussed in relation to the factors involved in active ...
[Inactivated vaccines against rhinopneumonitis in horses]. Attempts were made to produce inactivated vaccines against horse Herpes virus 1, using various inactivating agents and adjuvants, Best results were obtained with vaccine No 3 (glutaraldehide inactivator and "CTC" adjuvant). Used were two strains of the virus (St. Karaja and Varna). isolated in this country in cell cultures of a sucking pig kidney. Vaccine No 3 showed good immunogenic properties. Its application resulted in the full cease of abortions and respiratory diseases on the base of infection with the horse Herpes virus 1. The vaccination protects newborn colts from rhinopneumonitis if ...
Serologic responses of pregnant thoroughbred mares to vaccination with an inactivated equine herpesvirus 1 vaccine. The immunogenic potency and safety of a chemically inactivated equine herpesvirus 1 vaccine with added adjuvant was evaluated by testing serum-neutralizing and complement-fixation antibody responses of pregnant Thoroughbred mares. The vaccinated population comprised 321 pregnant mares on 7 farms; 3 in Normandy, France; 1 in Kildare, Ireland; and 3 in central Kentucky. The pattern of antibody response to vaccination was found qualitatively and quantitatively similar to that of pregnant mares previously vaccinated and determined by challenge exposure to be immune to abortigenic infection under e...
Response of pregnant mares to equine herpesvirus 1 (EHV1). Twenty-one pregnant mares were inoculated with EHV1. Nineteen became infected as evidenced by clinical signs and/or viremia but only one mare aborted a virus-infected fetus. The viremias were leukocyte-associated and appeared to be non-productive, latent infections of these cells. Infectivity, detectable by cocultivation, persisted in the circulating leukocytes for as long as 9 days without resulting in abortion. The data suggest that it is extremely difficult to evaluate the efficacy of vaccines in preventing EHV1 (Rhinopneumonitis) abortion due to the paucity of non-exposed mares, lack of te...
Combined active-passive immunisation of horses against tetanus. The protection afforded by active, passive and combined active-passive methods of immunisation against tetanus was examined in previously unimmunised horses. Three groups of horses were injected; one with tetanus toxoid alone, one with tetanus antitoxin alone and one in which the tetanus toxoid and tetanus antitoxin were injected simultaneously. The protection afforded was determined by monitoring the levels of antitoxin achieved in the horses by each of these methods. The results obtained demonstrated the effectiveness of the combined active-passive method in affording rapid and prolonged pro...
The immune response of horses to tetanus toxoid. An intramuscular injection of 8-16 Lf tetanus toxoid in water-in-oil emulsion protected adult horses against tetanus for at least 128 weeks. A booster dose of 8 Lf toxoid in aqueous solution protected them for a further period of at least 3 1/2 years. Colostral immunity protected foals for at least 10 weeks. An intramuscular injection of 8 Lf toxoid in water-in-oil emulsion given to foals from immune dams when they were 10-18 weeks old did not elicit any antibody response. They did respond, however, to a booster injection of 8 Lf toxoid in aqueous solution given 12 weeks after the first dose. ...
Studies on cross protection induced in calves by rotaviruses of calves, children and foals. Inoculation at birth with a live attenuated strain of a bovine rotavirus isolated in the USA (scourvax-reo) induced protection in five gnotobiotic calves seven to 21 days later against a UK isolate of pathogenic bovine rotavirus. However, no protection was induced in three calves challenged three to five days after vaccination. There was a close antigenic relationship demonstrated between the two bovine rotavirus isolates. In contrast only one of three gnotobiotic calves inoculated with foal rotavirus, and one of three with human rotavirus, were protected against bovine rotavirus challenge. Pr...
Homologous and cross-reactive precipitins in anti-pneumococcal sera raised in mules. Serial bleedings were obtained from two mules during prolonged immunization, one with type XXV the other with type VIII pneumococcal vaccine. IgGa, IgGb, IgGc, IgB, IgG(T) and IgM present among purified Pn anti-XXV and Pn anti-VIII immunoglobulin isolated from various bleedings were identified by use of rabbit anti-equine heavy chain specific reagents. Radioimmunodiffusion with 14C-labelled type XXV pneumococcal capsular polysaccharide and horse and donkey reagents with species specificity directed against donkey or horse IgGa respectively, demonstrated both parental horse and donkey IgGa heav...
Radioimmunoassay for quantitation of antibodies to alphaviruses with staphylococcal protein A. A radioimmunoassay (RIA) procedure is described for measuring antibodies to alphaviruses in human and other mammalian sera. The test employed protein Abearing Staphylococcus aureus as a solid-phase immunoadsorbent for (3)H-labeled viruses complexed with immunoglobulin G. Using antibodies produced in humans and guinea pigs, the RIA procedure clearly differentiated among antibodies to Venezuelan, western, and eastern equine encephalomyelitis viruses. Sensitivity of the RIA depended on the concentrations of labeled viruses employed. The dilution of serum that effected binding of 50% of the (3)H-l...
Equine rhinopneumonitis vaccine: immunogenicity and safety in foals. Immunogenicity and safety of an equine herpesvirus 1 (ehv-1) vaccine were studied in 111 foals varying in age from 1 to 122 days. Each of 88 principals was given 1 im injection of vaccine. Five of the 88 foals were revaccinated; 69 of the vaccinated principals and 23 nonvaccinated foals (serving as controls) were challenge exposed intranasally with virulent ehv-1.
The vaccine failed to cause adverse local or systemic reaction in 88 principals with serunirneutralization (sn) titers against ehv-1 varying between 0 to 1:256 at time of vaccination. After vaccination, the foals' body temperature...
Efficacy of trivalent inactivated encephalomyelitis virus vaccine in horses. Twenty-nine horses were vaccinated with a trivalent (Venezuelan, eastern, and western) inactivated equine encephalomyelitis virus vaccine. The vaccine purchased for this study was the only one licensed and commercially available in May, 1975. Plaque-neutralizing and hemagglutinin-inhibiting antibodies in response to each of the 3 equine encephalomyelitis viruses were determined after vaccination. Horses had rising levels of plaque-neutralizing and hemagglutinin-inhibiting antibodies shortly after injection with the 1st and 2nd doses of the vaccine (given 3 weeks apart) and were refractory to c...
Enzootic and epizootic Venezuelan equine encephalomyelitis virus in horses infected by peripheral and intrathecal routes. Forty-five horses were infected peripherally or intrathecally with enzootic or epizootic strains of Venezuelan equine encephalomyelitis (VEE) virus. Low titers of virus appeared in cerebrospinal fluid (CSF) after peripheral inoculation of enzootic or epizootic VEE virus strains. Intrathecal infection with either epizootic or enzootic VEE virus produced higher titers of virus in CSF than did peripheral infection. In contrast to peripheral infections with enzootic strains, intrathecal infections with these strains caused death. The animals that died had widespread histopathologic changes and lar...
Vaccination against diseases associated with herpesvirus infections in animals: a review. An account is presented of the development and use of herpesvirus vaccines in domestic animals, with particular reference to those viruses causing cytolytic rather than oncogenic infections. The chief infections covered are Aujeszky's disease (AD or pseudorabies), infectious bovine rhinotracheitis (IBR) and equine rhinopneumonitis (equine abortion; EHV-1). Others mentioned are feline viral rhinotracheitis and malignant catarrhal fever of cattle. Both live-modified and inactivated vaccines are widely used or under development for ADV, IBR and EHV-1. Live vaccines are generally regarded as succe...
A three-year evaluation of four commercial equine influenza vaccines in ponies maintained in isolation. Ponies held in isolation for 40 months were vaccinated and revaccinated with four commercial equine influenza vaccines. Little or no HI antibody was detected after the first inoculation; second and subsequent annual revaccinations produced peak HI antibody titres between 7 and 14 days. Titres fell quickly between 14 and 28 days and less quickly thereafter. The decline of HI antibody appeared to be related more to the initial titre attained and to the period after vaccination than to the composition of the vaccine. The response to a first annual revaccination was superior to that produced by a ...
[Outbreak of equine influenza by a new strain of Myxovirus type 2. II. Epizootiology]. During an epizootic of equine acute respiratory disease in Algeria, a strain of equine influenza virus was isolated. Sera examination by hemagglutinin inhibition test and complement fixation test confirmed the etiology of the disease. The first and second outbreak of the disease remained localised. The third outbreak spread within few months to all parts of the country. Horses vaccinated with a commercial equine influenza vaccine remained healthy.
Immunization of man and animals against influenza by oral and intranasal routes. Live human and equine influenza virus strains modified by serial passage on allantois-on-shell system (AOS) in the presence of normal horse serum were administered orally or intranasally to volunteers or horses. Mostly mild clinical short-lasting reactions, replication in nasal mucosae, transmission to placebo recipients and significant local or circulating antibody rises were observed following administration to volunteers of strains modified by five or less serial passages on AOS in the presence of normal horse serum (NHS). Milder clinical reactions, no replication, no viral transmission and...
Laboratory studies of Venezuelan equine encephalitis virus in equines, Texas, 1971. During the summer and fall of 1971, epizootic and epidemic Venezuelan equine encephalitis was detected in Texas. Isolates of epizootic (IB) and vaccine (TC-83) strains were distinguished by virulence of the former for guinea pigs. Vaccine virus was isolated from 1 to 14 days after vaccination and neutralization tests demonstrated the appearance of antibody about a week after vaccination. Viremia titers of subtype IB in horses ranged from 2.2 to 8.3 log10 suckling mouse intracranial 50% lethal doses per ml. Of 101 equines from which Venezuelan equine encephalitis virus (IB or TC-83) strains wer...
